Ken Griffin Terns Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 197,500 shares of TERN stock, worth $823,575. This represents 0.0% of its overall portfolio holdings.

Number of Shares

197,500

Previous 129,400 52.63%

Holding current value

$823,575

Previous $1.08 Million 2.13%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$5.53 - $8.36 $2.24 Million - $3.39 Million	-405,447 Reduced 11.04%	3,267,779 $18.2 Million
Q3 2024 Nov 14, 2024	BUY	$6.49 - $10.8 $14.4 Million - $23.9 Million	2,213,276 Added 151.6%	3,673,226 $30.6 Million
Q2 2024 Aug 14, 2024	SELL	$4.54 - $8.2 $6.84 Million - $12.3 Million	-1,505,636 Reduced 50.77%	1,459,950 $9.94 Million
Q1 2024 May 15, 2024	BUY	$4.86 - $8.19 $14.2 Million - $24 Million	2,930,946 Added 8461.16%	2,965,586 $19.5 Million
Q4 2023 Feb 14, 2024	SELL	$3.37 - $6.86 $138,513 - $281,959	-41,102 Reduced 54.27%	34,640 $224,000
Q3 2023 Nov 14, 2023	BUY	$4.7 - $8.55 $349,144 - $635,145	74,286 Added 5102.06%	75,742 $380,000
Q2 2023 Aug 14, 2023	SELL	$7.35 - $13.29 $2.87 Million - $5.19 Million	-390,609 Reduced 99.63%	1,456 $12,000
Q1 2023 May 15, 2023	SELL	$7.91 - $12.0 $978,720 - $1.48 Million	-123,732 Reduced 23.99%	392,065 $4.64 Million
Q4 2022 Feb 14, 2023	BUY	$4.62 - $10.18 $2.38 Million - $5.25 Million	515,797 New	515,797 $5.25 Million

Others Institutions Holding TERN

# of Institutions

160

Shares Held

83.7M

Call Options Held

484K

Put Options Held

141K

View Full List

About Terns Pharmaceuticals, Inc.

Ticker TERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,613,800
Market Cap $157M
Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...

More about TERN

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account